Apellis Pharmaceuticals (APLS) investor relations material

Product portfolio and recent approvals

• Four indications approved in three and a half years, including recent launches for C3G and IC-MPGN.

• SYFOVRE has reached a mature phase with a $600 million run rate and growth opportunities in the coming year.

• EMPAVELI's new indications launched in August, with 152 start forms in the first two months.

• Both drugs are seen as having blockbuster potential by 2026.

• The company leverages a foundational C3 complement cascade technology.

Market dynamics and growth strategies

• SYFOVRE faces headwinds from copay funding and free product, impacting $40–$50 million in potential revenue.

• Efficacy messaging, new five-year GALE study data, and a prefilled syringe are key growth drivers for SYFOVRE.

• Expansion efforts target general ophthalmology and optometry to increase referrals to retinal specialists.

• Patient assistance and free goods programs are used to maintain access amid reimbursement challenges.

• Injection volumes for SYFOVRE are growing 4–6% per quarter despite market headwinds.

EMPAVELI launch and physician adoption

• EMPAVELI's broad label, including pediatric and post-transplant populations, is well received by nephrologists.

• Early adoption includes both new and switch patients, with compliance favored by twice-weekly dosing.

• Position papers and KOL influence expected to accelerate adoption within 4–6 months.

• Patient onboarding takes 4–6 weeks, expected to shorten as payer policies mature.

• Total addressable market for EMPAVELI is estimated at 5,000 patients, with annual drug cost around $500,000.